Cargando…
Accelerated ischemic vascular retinopathy after intravitreally injected bevacizumab for central retinal vein occlusion in elderly patients
BACKGROUND: Ischemic changes in the retinal circulation are an uncommon but severe adverse vascular reaction to intravitreal bevacizumab (Avastin(®), Genentech, San Francisco, CA, USA/Roche, Basel, Switzerland) for central retinal vein occlusion (CRVO). In the two cases reported here, ischemic chang...
Autores principales: | Isola, Vincenzo, Pece, Alfredo, Massironi, Claudio, Reposi, Simone, Dimastrogiovanni, Fabio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589185/ https://www.ncbi.nlm.nih.gov/pubmed/23467497 http://dx.doi.org/10.2147/OPTH.S30156 |
Ejemplares similares
-
Prospective evaluation of intravitreal bevacizumab for ischemic central retinal vein occlusion
por: Hall, Leangelo, et al.
Publicado: (2019) -
Progression of Impending Central Retinal Vein Occlusion to the Ischemic Variant Following Intravitreal Bevacizumab
por: Kim, Na Rae, et al.
Publicado: (2010) -
Rebound effect following intravitreal bevacizumab in branch retinal vein occlusion
por: Deka, Satyen, et al.
Publicado: (2009) -
Efficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion
por: Ali, Rasha I, et al.
Publicado: (2014) -
Intravitreal bevacizumab upregulates transthyretin in experimental branch retinal vein occlusion
por: Cehofski, Lasse Jørgensen, et al.
Publicado: (2018)